Detection of ASO drug activity in DMD patients involves multiple muscle biopsies to examine whether the target exon has been removed from the mRNA, and quantification of dystrophin protein production by immunofluorescence and western blotting44. Here, DMD is linked to Duchenne muscular dystrophy.